<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116412</article-id><article-id pub-id-type="publisher-id">ACM-43446</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_67750938.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  阿替普酶联合替罗非班治疗穿支动脉闭塞性脑梗死的疗效及安全性
  Efficacy and Safety of Alteplase Combined with Tirofiban in the Treatment of Perforating Artery Occlusive Cerebral Infarction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>振红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>畅</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>振文</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>仰亮</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>可可</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>济宁医学院附属湖西医院，山东 菏泽</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院神经内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2836</fpage><lpage>2843</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨穿支动脉性脑梗死患者在应用阿替普酶(alteplase, rt-PA)静脉溶栓后无效或再闭塞，应用替罗非班(Tirofiban)治疗的疗效、安全性及治疗前后体内尿酸(Uricacid, UA)水平变化。方法：选取2020年1月至2020年12月我院神经内科收治的急性穿支动脉闭塞性脑梗死(Acute perforator artery occlusive cerebral infarction, APCI)患者30例，作为观察组，本组患者在rt-PA静脉溶栓后无效或症状进行性加重，于溶栓后24小时内给予替罗非班治疗。年龄与性别相匹配的同期入院的另30例APCI患者，作为对照组，此组患者只给予rt-PA静脉溶栓治疗。比较两组患者治疗前后NIHSS评分、mRs评分、不良事件发生率(卒中后抑郁、再梗死、脑出血、死亡)等指标及治疗前后两组患者体内尿酸水平。结果：两组患者NIHSS评分在溶栓前[(4.07 &#177; 3.10) vs (4.33 &#177; 3.39), P &gt; 0.05]、加重时[(7.80 &#177; 3.22) vs (7.83 &#177; 3.36), P &gt; 0.05]、溶栓后24小时[(3.73 &#177; 3.60) vs (5.43 &#177; 3.81), P &gt; 0.05]差异无统计学意义；溶栓后7天[(2.73 &#177; 2.64) vs (4.33 &#177; 2.76), P &lt; 0.05]、溶栓后14天[(2.13 &#177; 2.26) vs (3.53 &#177; 2.24), P &lt; 0.05]差异有统计学意义。两组患者mRs评分在溶栓前[(1.93 &#177; 1.17) vs (2.13 &#177; 1.22), P &gt; 0.05]、加重时[(3.37 &#177; 1.30) vs (3.87 &#177; 1.25), P &gt; 0.05]、溶栓后24小时[(2.17 &#177; 1.37) vs (2.90 &#177; 1.52), P &gt; 0.05]差异无统计学意义，溶栓后14天[(1.63 &#177; 1.03) vs (2.40 &#177; 1.25), P &lt; 0.05]、溶栓后90天[(0.87 &#177; 1.01) vs (1.63 &#177; 0.93), P &lt; 0.05]差异有统计学意义。两组患者不良事件发生率，观察组，卒中后抑郁[3.3% vs 26.6%, P &lt; 0.05]、再梗死[6.6% vs 36.6%, P &lt; 0.05]显著低于对照组。脑出血[10% vs 3.0%, P &gt; 0.05]、死亡[3.3% vs 10%, P &gt; 0.05]，差异无统计学意义。治疗前两组尿酸水平对比[(252.37 &#177; 96.06) vs (263.73 &#177; 85.97), P &gt; 0.05]，差异无统计学意义，治疗后两组尿酸水平对比[(195.04 &#177; 72.75) vs (239.90 &#177; 74.75), P &lt; 0.05]，差异有统计学意义。结论：对于穿支动脉闭塞性脑梗死，静脉溶栓后无效或24小时内进行性加重，早期给予替罗非班泵入治疗可以改善预后、不增加出血风险，降低体内尿酸水平。
   Objective: To investigate the efficacy and safety of Tirofiban and the changes of uric acid levels in patients with perforating artery cerebral infarction after intravenous thrombolysis with alteplase (rt-PA). Methods: Thirty patients with Acute perforator artery occlusive cerebral infarction (APCI) admitted to the Department of Neurosurgery in our hospital from January 2020 to December 2020 were selected as the observation group. Patients in this group were treated with tirofiban within 24 hours after intravenous thrombolysis for ineffective rt-PA or progressive exacerbation of symptoms. Another 30 patients with APCI who matched their age and gender during the same period were admitted as the control group, and only rt-PA intravenous thrombolytic therapy was given in this group. NIHSS score, mRs score, incidence of adverse events (post-stroke depression, reinfarction, cerebral hemorrhage, death) and the level of uric acid in two groups before and after treatment were compared. Results: NIHSS score in the two groups was significantly higher than that in patients before thrombolysis [(4.07 &#177; 3.10) vs (4.33 &#177; 3.39), P &gt; 0.05] and in patients with exacerbation [(7.80 &#177; 3.22) vs (7.83 &#177; 3.36), P &gt; 0.05], 24 hours after thrombolysis [(3.73 &#177; 3.60) vs (5.43 &#177; 3.81), P &gt; 0.05], there was no statistical significance. 7 days after thrombolysis [(2.73 &#177; 2.64) vs (4.33 &#177; 2.76), P &lt; 0.05]; the difference was statistically significant 14 days after thrombolysis [(2.13 &#177; 2.26) vs (3.53 &#177; 2.24), P &lt; 0.05]. The mRs scores of the two groups were [(1.93 &#177; 1.17) vs (2.13 &#177; 1.22), P &gt; 0.05] before thrombolysis, [(3.37 &#177; 1.30) vs (3.87 &#177; 1.25), P &gt; 0.05] when aggravating, [(2.17 &#177; 1.37) vs (2.90 &#177; 1.52), P &gt; 0.05] 24 hours after thrombolysis, which had no statistical significance. The difference was statistically significant 14 days after thrombolysis [(1.63 &#177; 1.03) vs (2.40 &#177; 1.25), P &lt; 0.05] and 90 days after thrombolysis [(0.87 &#177; 1.01) vs (1.63 &#177; 0.93), P &lt; 0.05]. The incidence of adverse events, observation group, post-stroke depression [3.3% vs 26.6%, P &lt; 0.05] and reinfarction [6.6% vs 36.6%, P &lt; 0.05] in 2 groups were significantly lower than those in control group. Intracerebral hemorrhage [10% vs 3.0%, P &gt; 0.05] and death [3.3% vs 10%, P &gt; 0.05] were not statistically significant. Before treatment, there was no statistically significant difference in uric acid levels between the two groups [(252.37 &#177; 96.06) vs (263.73 &#177; 85.97), P &gt; 0.05]. After treatment, there was statistically significant difference in uric acid levels between the two groups [(195.04 &#177; 72.75) vs (239.90 &#177; 74.75), P &lt; 0.05]. Conclusion: For perforating artery occlusive cerebral infarction, it is progressively worse within 24 hours after intravenous thrombolysis. Early administration of tirofiban pump therapy can improve the prognosis without increasing the risk of bleeding, and reduce in vivo uric acid level.
 
</p></abstract><kwd-group><kwd>脑梗死，穿支动脉，再闭塞，静脉溶栓，替罗非班, Cerebral Infarction</kwd><kwd> Perforating Artery</kwd><kwd> Reocclusion</kwd><kwd> Intravenous Thrombolysis</kwd><kwd> Tirofiban</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨穿支动脉性脑梗死患者在应用阿替普酶(alteplase, rt-PA)静脉溶栓后无效或再闭塞，应用替罗非班(Tirofiban)治疗的疗效、安全性及治疗前后体内尿酸(Uricacid, UA)水平变化。方法：选取2020年1月至2020年12月我院神经内科收治的急性穿支动脉闭塞性脑梗死(Acute perforator artery occlusive cerebral infarction, APCI)患者30例，作为观察组，本组患者在rt-PA静脉溶栓后无效或症状进行性加重，于溶栓后24小时内给予替罗非班治疗。年龄与性别相匹配的同期入院的另30例APCI患者，作为对照组，此组患者只给予rt-PA静脉溶栓治疗。比较两组患者治疗前后NIHSS评分、mRs评分、不良事件发生率(卒中后抑郁、再梗死、脑出血、死亡)等指标及治疗前后两组患者体内尿酸水平。结果：两组患者NIHSS评分在溶栓前[(4.07 &#177; 3.10) vs (4.33 &#177; 3.39), P &gt; 0.05]、加重时[(7.80 &#177; 3.22) vs (7.83 &#177; 3.36), P &gt; 0.05]、溶栓后24小时[(3.73 &#177; 3.60) vs (5.43 &#177; 3.81), P &gt; 0.05]差异无统计学意义；溶栓后7天[(2.73 &#177; 2.64) vs (4.33 &#177; 2.76), P &lt; 0.05]、溶栓后14天[(2.13 &#177; 2.26) vs (3.53 &#177; 2.24), P &lt; 0.05]差异有统计学意义。两组患者mRs评分在溶栓前[(1.93 &#177; 1.17) vs (2.13 &#177; 1.22), P &gt; 0.05]、加重时[(3.37 &#177; 1.30) vs (3.87 &#177; 1.25), P &gt; 0.05]、溶栓后24小时[(2.17 &#177; 1.37) vs (2.90 &#177; 1.52), P &gt; 0.05]差异无统计学意义，溶栓后14天[(1.63 &#177; 1.03) vs (2.40 &#177; 1.25), P &lt; 0.05]、溶栓后90天[(0.87 &#177; 1.01) vs (1.63 &#177; 0.93), P &lt; 0.05]差异有统计学意义。两组患者不良事件发生率，观察组，卒中后抑郁[3.3% vs 26.6%, P &lt; 0.05]、再梗死[6.6% vs 36.6%, P &lt; 0.05]显著低于对照组。脑出血[10% vs 3.0%, P &gt; 0.05]、死亡[3.3% vs 10%, P &gt; 0.05]，差异无统计学意义。治疗前两组尿酸水平对比[(252.37 &#177; 96.06) vs (263.73 &#177; 85.97), P &gt; 0.05]，差异无统计学意义，治疗后两组尿酸水平对比[(195.04 &#177; 72.75) vs (239.90 &#177; 74.75), P &lt; 0.05]，差异有统计学意义。结论：对于穿支动脉闭塞性脑梗死，静脉溶栓后无效或24小时内进行性加重，早期给予替罗非班泵入治疗可以改善预后、不增加出血风险，降低体内尿酸水平。</p></sec><sec id="s2"><title>关键词</title><p>脑梗死，穿支动脉，再闭塞，静脉溶栓，替罗非班</p></sec><sec id="s3"><title>Efficacy and Safety of Alteplase Combined with Tirofiban in the Treatment of Perforating Artery Occlusive Cerebral Infarction<sup> </sup></title><p>Zhenhong Gao<sup>1</sup>, Chang Zhou<sup>2*</sup>, Zhenwen Gao<sup>3</sup>, Yangliang Wang<sup>3</sup>, Keke Shao<sup>3</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>The Affiliated Huxi Hospital of Jining Medical College, Heze Shandong</p><p><img src="//html.hanspub.org/file/54-1572287x5_hanspub.png" /></p><p>Received: May 21<sup>st</sup>, 2021; accepted: Jun. 9<sup>th</sup>, 2021; published: Jun. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/54-1572287x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the efficacy and safety of Tirofiban and the changes of uric acid levels in patients with perforating artery cerebral infarction after intravenous thrombolysis with alteplase (rt-PA). Methods: Thirty patients with Acute perforator artery occlusive cerebral infarction (APCI) admitted to the Department of Neurosurgery in our hospital from January 2020 to December 2020 were selected as the observation group. Patients in this group were treated with tirofiban within 24 hours after intravenous thrombolysis for ineffective rt-PA or progressive exacerbation of symptoms. Another 30 patients with APCI who matched their age and gender during the same period were admitted as the control group, and only rt-PA intravenous thrombolytic therapy was given in this group. NIHSS score, mRs score, incidence of adverse events (post-stroke depression, reinfarction, cerebral hemorrhage, death) and the level of uric acid in two groups before and after treatment were compared. Results: NIHSS score in the two groups was significantly higher than that in patients before thrombolysis [(4.07 &#177; 3.10) vs (4.33 &#177; 3.39), P &gt; 0.05] and in patients with exacerbation [(7.80 &#177; 3.22) vs (7.83 &#177; 3.36), P &gt; 0.05], 24 hours after thrombolysis [(3.73 &#177; 3.60) vs (5.43 &#177; 3.81), P &gt; 0.05], there was no statistical significance. 7 days after thrombolysis [(2.73 &#177; 2.64) vs (4.33 &#177; 2.76), P &lt; 0.05]; the difference was statistically significant 14 days after thrombolysis [(2.13 &#177; 2.26) vs (3.53 &#177; 2.24), P &lt; 0.05]. The mRs scores of the two groups were [(1.93 &#177; 1.17) vs (2.13 &#177; 1.22), P &gt; 0.05] before thrombolysis, [(3.37 &#177; 1.30) vs (3.87 &#177; 1.25), P &gt; 0.05] when aggravating, [(2.17 &#177; 1.37) vs (2.90 &#177; 1.52), P &gt; 0.05] 24 hours after thrombolysis, which had no statistical significance. The difference was statistically significant 14 days after thrombolysis [(1.63 &#177; 1.03) vs (2.40 &#177; 1.25), P &lt; 0.05] and 90 days after thrombolysis [(0.87 &#177; 1.01) vs (1.63 &#177; 0.93), P &lt; 0.05]. The incidence of adverse events, observation group, post-stroke depression [3.3% vs 26.6%, P &lt; 0.05] and reinfarction [6.6% vs 36.6%, P &lt; 0.05] in 2 groups were significantly lower than those in control group. Intracerebral hemorrhage [10% vs 3.0%, P &gt; 0.05] and death [3.3% vs 10%, P &gt; 0.05] were not statistically significant. Before treatment, there was no statistically significant difference in uric acid levels between the two groups [(252.37 &#177; 96.06) vs (263.73 &#177; 85.97), P &gt; 0.05]. After treatment, there was statistically significant difference in uric acid levels between the two groups [(195.04 &#177; 72.75) vs (239.90 &#177; 74.75), P &lt; 0.05]. Conclusion: For perforating artery occlusive cerebral infarction, it is progressively worse within 24 hours after intravenous thrombolysis. Early administration of tirofiban pump therapy can improve the prognosis without increasing the risk of bleeding, and reduce in vivo uric acid level.</p><p>Keywords:Cerebral Infarction, Perforating Artery, Reocclusion, Intravenous Thrombolysis, Tirofiban</p><disp-formula id="hanspub.43446-formula53"><graphic xlink:href="//html.hanspub.org/file/54-1572287x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/54-1572287x8_hanspub.png" /> <img src="//html.hanspub.org/file/54-1572287x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性脑梗死发病4.5小时内最有效的治疗方法为阿替普酶(rt-PA)静脉溶栓 [<xref ref-type="bibr" rid="hanspub.43446-ref1">1</xref>]，它可溶解血栓，减少缺血半暗带脑细胞损伤，缩小梗死面积，促进神经功能恢复，改善临床预后，但血管再通率为46% [<xref ref-type="bibr" rid="hanspub.43446-ref2">2</xref>] 左右，静脉溶栓后有11.8%左右患者出现神经功能恶化，其中82%患者出现再闭塞 [<xref ref-type="bibr" rid="hanspub.43446-ref3">3</xref>]，甚至导致患者死亡，加重医疗负担。穿支动脉闭塞性脑梗死在脑梗死中占25%~30% [<xref ref-type="bibr" rid="hanspub.43446-ref4">4</xref>] 左右，静脉溶栓后血管再闭塞可导致神经功能进行性恶化，由于穿支动脉管径小，无法行介入治疗，加之静脉溶栓后24小时内指南不推荐加用口服抗血小板聚集药物，导致患者致残率、死亡率升高，使临床工作被动。替罗非班为第三代抗血小板聚集药物，可直接作用于GPIIb/IIIa受体，具有抗血小板聚集功能，其半衰期短，无抗原性，不良反应少。本研究以我院穿支动脉闭塞性脑梗死患者为研究对象，给予rt-PA静脉溶栓后无效或再闭塞，桥接替罗非班泵入治疗，旨在探讨其疗效及安全性。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 资料选取</title><p>选取2020年1月至2020年12月我院神经内科收治的急性穿支动脉闭塞性脑梗死(Acute perforator artery occlusive cerebral infarction, APCI)患者30例，作为观察组，纳入标准：1) 符合缺血性卒中诊断标准 [<xref ref-type="bibr" rid="hanspub.43446-ref5">5</xref>]，发病4.5小时内，符合静脉溶栓标准，经患者家属知情同意，给予rt-PA溶栓治疗。2) 给予rt-PA静脉溶栓后无效，NIHSS评分 ≥ 5分或静脉溶栓有效，NIHSS评分改善2分以上，溶栓24小时内发生再闭塞，NIHSS评分较溶栓后增加2分以上，颅脑CT排除出血。3) MRA、CTA或DSA发现脑梗死位于穿支动脉供血区。排除标准：1) 伴有感染性疾病或存在溶栓治疗禁忌证者；2) MRA或CTA、DSA等血管检查有颅内外动脉狭窄或闭塞者，且为本次发病责任血管；3) 合并重要脏器功能衰竭；4) 既往脑出血、精神病史以及椎管手术者。本组患者男12例，女18例，年龄44~75岁，平均年龄(64.21 &#177; 6.74)岁，在rt-PA静脉溶栓后无效或再闭塞，经患者或家属知情同意，于溶栓后24小时内给予替罗非班治疗。年龄与性别相匹配的同期入院的另30例APCI患者，男13例，女17例，年龄44~74岁，平均年龄(64.1 &#177; 46.72)岁，作为对照组，患者或家属拒绝替罗非班治疗，只给予rt-PA静脉溶栓治疗。</p><p>两组患者的年龄、性别、高血压史、糖尿病史、吸烟史、低密度脂蛋白、总胆固醇等资料比较无统计学意义(P &gt; 0.05)，见表1。本研究所有入选对象均经过医院伦理委员会批准，并签署知情同意书。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Observation group and control group basic document compariso</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >观察组(n = 30)</th><th align="center" valign="middle" >对照组(n = 30)</th><th align="center" valign="middle" >t/χ<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >64.21 &#177; 6.74</td><td align="center" valign="middle" >64.1 &#177; 46.72</td><td align="center" valign="middle" >0.623</td><td align="center" valign="middle" >0.514</td></tr><tr><td align="center" valign="middle" >性别(男/女)</td><td align="center" valign="middle" >12/18</td><td align="center" valign="middle" >13/17</td><td align="center" valign="middle" >0.041</td><td align="center" valign="middle" >0.750</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >高血压</th><th align="center" valign="middle" >11 (36.67%)</th><th align="center" valign="middle" >13 (43.3%)</th><th align="center" valign="middle" >0.208</th><th align="center" valign="middle" >0.609</th></tr></thead><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >9 (30.00%)</td><td align="center" valign="middle" >7 (23.4%)</td><td align="center" valign="middle" >1.892</td><td align="center" valign="middle" >0.173</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >10 (33.4%)</td><td align="center" valign="middle" >12 (40.0%)</td><td align="center" valign="middle" >0.283</td><td align="center" valign="middle" >0.602</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mmol/L)</td><td align="center" valign="middle" >2.72 &#177; 0.41</td><td align="center" valign="middle" >2.76 &#177; 0.36</td><td align="center" valign="middle" >1.372</td><td align="center" valign="middle" >0.235</td></tr><tr><td align="center" valign="middle" >总胆固醇(mmol/L)</td><td align="center" valign="middle" >4.83 &#177; 1.75</td><td align="center" valign="middle" >4.79 &#177; 1.36</td><td align="center" valign="middle" >0.403</td><td align="center" valign="middle" >0.658</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 观察组和对照组基本资料的比较</p></sec><sec id="s6_2"><title>2.2. 治疗方法</title><p>观察组给予rt-PA(德国柏林格殷格翰公司，批准文号：S20110051)静脉溶栓，剂量按0.9 mg/kg，总量不超过90 mg，10%给予静脉推注(1 min)，剩余90%给予静脉输液(持续60 min)，在溶栓后无效或24小时内症状进行性加重，MRA或CT A发现脑梗死位于穿支动脉供血区，且无出血症状，给予替罗非班(欣维宁，远大医药有限公司，国药准字H20041165)治疗，剂量按0.4 ug/kg∙min计算，30分钟后给予按0.1 ug/kg∙min计算，持续泵入24小时，复查颅脑CT，无脑出血时给予双抗(拜阿司匹林肠溶片：拜耳医药公司，国药准字：J20130078；硫酸氢氯吡格雷片：波立维，赛诺菲制药有限公司，国药准字H20056410)治疗，拜阿司匹林肠溶片采用0.1 g 1次/日，硫酸氢氯吡格雷片75 mg 1次/日，双抗治疗21天，根据血栓弹力图AA+ADP结果，决定出院后服用二级预防药物。</p><p>对照组采用同观察组一样规格rt-PA溶栓治疗，MRA或CTA发现脑梗死位于穿支动脉供血区，24小时后复查颅脑CT无出血，给予双抗(同观察组)治疗21天，根据血栓弹力图AA+ADP结果，决定出院后服用二级预防药物。两组均给予吸氧、心电监护、降脂、清除自由基、改善微循环、调控血压、血糖及对症支持治疗，病情平稳后给予康复治疗。</p></sec><sec id="s6_3"><title>2.3. 疗效评估</title><p>1) 采用美国国立卫生研究院卒中量表(NIHSS评分) [<xref ref-type="bibr" rid="hanspub.43446-ref6">6</xref>]，进行神经功能缺损评估，分别观察溶栓前、加重时、用药24小时、用药后7天、用药后14天的NIHSS评分。2) 采用Rankin评分量表(mRs评分) [<xref ref-type="bibr" rid="hanspub.43446-ref7">7</xref>] 评估患者临床预后，分别观察溶栓前、加重时、24小时、14天、90天的mRs评分。3) 不良事件发生率：统计卒中后抑郁、再梗死、脑出血、死亡率等。4) 检测两组治疗前后尿酸(UA)水平。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 23.0统计学软件对数据进行统计分析，计量资料以均数 &#177; 标准差( x &#175; &#177; s )表示，两组比较采用成组设计t检验，治疗前后比较采用配对t检验；计数资料以率表示，采用χ<sup>2</sup>检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. NIHSS评分比较</title><p>两组治疗前、加重时、用药24小时的NIHSS评分比较，差异无统计学意义，(P &gt; 0.05)；用药7天、用药14天的NIHSS评分比较，差异有统计学意义(P &lt; 0.05)。见表2。</p></sec><sec id="s7_2"><title>3.2. mRs评分比较</title><p>两组治疗前、加重时、用药24小时的mRs评分比较，差异无统计学意义，(P &gt; 0.05)；用药14天、90天mRs评分比较，差异有统计学意义(P &lt; 0.05)。见表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of NIHSS scores between observation group and control group before and after treatment (minutes, x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >加重时</th><th align="center" valign="middle" >24小时</th><th align="center" valign="middle" >7天</th><th align="center" valign="middle" >14天</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >4.07 &#177; 3.10</td><td align="center" valign="middle" >7.80 &#177; 3.22</td><td align="center" valign="middle" >3.73 &#177; 3.60</td><td align="center" valign="middle" >2.73 &#177; 2.64</td><td align="center" valign="middle" >2.13 &#177; 2.26</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >4.33 &#177; 3.39</td><td align="center" valign="middle" >7.83 &#177; 3.36</td><td align="center" valign="middle" >5.43 &#177; 3.81</td><td align="center" valign="middle" >4.33 &#177; 2.76</td><td align="center" valign="middle" >3.53 &#177; 2.24</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.318</td><td align="center" valign="middle" >−0.039</td><td align="center" valign="middle" >−1.776</td><td align="center" valign="middle" >−2.296</td><td align="center" valign="middle" >−2.413</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.751</td><td align="center" valign="middle" >0.969</td><td align="center" valign="middle" >0.081</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >0.019</td></tr></tbody></table></table-wrap><p>表2. 观察组与对照组治疗前后NIHSS评分比较(分， x &#175; &#177; s )</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of mRs scores between the two groups before and after treatment (minutes, </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >加重时</th><th align="center" valign="middle" >24小时</th><th align="center" valign="middle" >14天</th><th align="center" valign="middle" >90天</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >1.93 &#177; 1.17</td><td align="center" valign="middle" >3.37 &#177; 1.30</td><td align="center" valign="middle" >2.17 &#177; 1.37</td><td align="center" valign="middle" >1.63 &#177; 1.03</td><td align="center" valign="middle" >0.87 &#177; 1.01</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >2.13 &#177; 1.22</td><td align="center" valign="middle" >3.87 &#177; 1.25</td><td align="center" valign="middle" >2.90 &#177; 1.52</td><td align="center" valign="middle" >2.40 &#177; 1.25</td><td align="center" valign="middle" >1.63 &#177; 0.93</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.646</td><td align="center" valign="middle" >−1.518</td><td align="center" valign="middle" >−1.967</td><td align="center" valign="middle" >−2.591</td><td align="center" valign="middle" >−3.065</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.521</td><td align="center" valign="middle" >0.969</td><td align="center" valign="middle" >0.081</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >0.019</td></tr></tbody></table></table-wrap><p>表3. 两组治疗前后mRs评分比较(分， x &#175; &#177; s )</p></sec><sec id="s7_3"><title>3.3. 不良事件发生率</title><p>1) 卒中后抑郁：观察组出现1例(3.3%)，对照组出现8例(26.6%)，采用汉密尔顿抑郁量表评估，两组间比较差异有统计学意义(P &lt; 0.05)。2) 再梗死：观察组在应用替罗非班24小时~48小时出现2例(6.6%)，对照组中出现11例(36.6%)，两组间再梗死的比例差异有统计学意义(P &lt; 0.05)。3) 脑出血的发生率：观察组3例(10%)，对照组1例(3.3%)，两组间比较差异无统计学意义(P &gt; 0.05)。4) 死亡率：观察组死亡1例(3.3%)，对照组3例(10%)，差异无统计学意义(P &gt; 0.05)，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of the occurrence of adverse events between the two groups of patients [n(%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >卒中后抑郁</th><th align="center" valign="middle" >再梗死</th><th align="center" valign="middle" >脑出血的发生率</th><th align="center" valign="middle" >死亡率</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >1 (3.3%)</td><td align="center" valign="middle" >2 (6.6%)</td><td align="center" valign="middle" >3 (10%)</td><td align="center" valign="middle" >1 (3.3%)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >8 (26.6%)</td><td align="center" valign="middle" >11 (36.6%)</td><td align="center" valign="middle" >1 (3.3%)</td><td align="center" valign="middle" >3 (10%)</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.030</td><td align="center" valign="middle" >0.012</td><td align="center" valign="middle" >0.605</td><td align="center" valign="middle" >0.605</td></tr></tbody></table></table-wrap><p>表4. 两组患者不良事件发生情况的比较[n(%)]</p></sec><sec id="s7_4"><title>3.4. 治疗前后两组患者体内尿酸水平</title><p>治疗前两组尿酸水平对比，差异无统计学意义(P &gt; 0.05)；治疗后两组尿酸水平对比，差异有统计学意义(P &lt; 0.05)。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Two group of patient uricacid level comparison (umol/L, x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >252.37 &#177; 96.06</td><td align="center" valign="middle" >195.43 &#177; 72.75</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >263.73 &#177; 85.98</td><td align="center" valign="middle" >239.90 &#177; 74.75</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.48</td><td align="center" valign="middle" >−2.34</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.63</td><td align="center" valign="middle" >0.02</td></tr></tbody></table></table-wrap><p>表5. 两组治疗前后尿酸水平比较(umol/L, x &#175; &#177; s )</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>脑梗死(cerebral infarction, CI)又称缺血性脑卒中(cerebral ischemic stroke, CIS)，是指脑血管病变致脑组织血液供应障碍，导致局部脑细胞缺血、缺氧性坏死，而迅速出现相应神经功能障碍的一类临床综合征，约占全部脑卒中的70%~80%。由于经济条件及医疗条件改善，大动脉重度狭窄或闭塞型脑梗死在静脉溶栓后，需要进一步介入治疗(包括动脉溶栓、桥接、机械取栓、血管成形和支架术等)，预防病情进一步恶化而危及生命。穿支动脉闭塞性脑梗死在脑梗死中占25%~30% [<xref ref-type="bibr" rid="hanspub.43446-ref4">4</xref>]，穿支动脉是大动脉分出的小动脉，一般直径 &lt; 1 mm，在其周围没有吻合支，当载体动脉出现病变或穿支动脉本身粥样硬化、血管玻璃化或纤维化等时，穿支动脉供血区可发生梗死 [<xref ref-type="bibr" rid="hanspub.43446-ref8">8</xref>]，导致患者出现肢体瘫痪、言语不利，甚至昏迷等，影响患者神经功能和日常生活能力 [<xref ref-type="bibr" rid="hanspub.43446-ref9">9</xref>]，致残率和致死率较高。脑梗死发病4.5小时内最有效治疗方法为静脉溶栓 [<xref ref-type="bibr" rid="hanspub.43446-ref1">1</xref>]，rt-PA作为一种静脉溶栓药物，在临床工作中主要用于治疗肺栓塞、急性心肌梗死及急性脑梗死等疾病 [<xref ref-type="bibr" rid="hanspub.43446-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.43446-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43446-ref12">12</xref>]。它可对体内相应的纤维蛋白进行特异性溶解，可实现血管再通，减少缺血半暗带面积，降低致残率、死亡率，血管再通率为46% [<xref ref-type="bibr" rid="hanspub.43446-ref2">2</xref>] 左右，但静脉溶栓后有11.8%左右患者出现神经功能恶化，其中82%患者出现再闭塞 [<xref ref-type="bibr" rid="hanspub.43446-ref3">3</xref>]，甚至导致患者死亡，加重医疗负担。出现再闭塞是由于溶栓后遗留的血栓以及内皮损伤等，可导致再通血管出现第二次血管闭塞。抗血小板聚集治疗是缺血性脑血管病治疗的根本，在rt-PA静脉溶栓后24小时内，排除脑出血及其他部位出血等情况下，存在脑血管再闭塞，症状进行性加重，若立即采用口服抗血小板药物(目前主要为阿司匹林、氯吡格雷)治疗，可增加出血风险，故指南不推荐溶栓后24小时内给予口服抗血小板药物治疗，故需寻找其它抗血小板聚集药物，既能避免病情进一步加重，又能预防出血等不良事件发生。替罗非班为第三代抗血小板聚集药物，是目前国内最主要的GPIIb/IIIa受体拮抗剂(GPIIb/IIIa inhibitor, GPI)，它属于小分子非肽类络氨酸衍生物，可逆的选择性竞争抑制GPIIb/IIIa受体，作用于血小板聚集的最后通路，在静脉注射后5 min内即可发挥抑制血小板聚集的作用 [<xref ref-type="bibr" rid="hanspub.43446-ref13">13</xref>]，用药1 h内可达稳态，半衰期短(1.4~1.8 h)，约1/2的患者停药4 h后血小板聚集功能恢复 [<xref ref-type="bibr" rid="hanspub.43446-ref14">14</xref>]，不良反应较少。目前替罗非班在合并大脑大血管狭窄或闭塞性脑梗死或桥接介入治疗中广泛应用，效果及安全性已得到认证 [<xref ref-type="bibr" rid="hanspub.43446-ref15">15</xref>]。邱涛等 [<xref ref-type="bibr" rid="hanspub.43446-ref16">16</xref>] 研究表明应用替罗非班联合小牛血清去蛋白治疗进展性脑梗死，可改善预后，提高患者生活质量。SaTIS [<xref ref-type="bibr" rid="hanspub.43446-ref17">17</xref>] 研究证实急性脑梗死应用替罗非班是有效且安全的。PHILLPPS [<xref ref-type="bibr" rid="hanspub.43446-ref18">18</xref>] 等研究证实对于穿支动脉闭塞引起的进展性脑梗死应用替罗非班是有效的，对于合并大动脉闭塞患者效果差。孙原 [<xref ref-type="bibr" rid="hanspub.43446-ref19">19</xref>] 等研究证实在急性缺血性脑卒中患者rt-PA静脉溶栓后桥接替罗非班治疗能显著增加再通率，减少再闭塞率，且未增加出血、死亡等风险。</p><p>本研究针对临床工作中遇到的急性穿支动脉闭塞性脑梗死患者，急性发病4.5小时内，给予rt-PA静脉溶栓，溶栓后无效或再闭塞，于静脉溶栓24小时内给予替罗非班治疗。研究显示，从NIHSS评分上看，溶栓前、加重时、用药24小时差异无统计学意义(P &gt; 0.05)，用药7天、14天差异有统计学意义(P &lt; 0.05)，可以看出溶栓后7天、14天时，观察组NIHSS评分均明显低于对照组(P &lt; 0.05)，表明穿支动脉脑梗死静脉溶栓后无效或再闭塞早期给予替罗非班治疗可以有效的改善患者的近期神经功能.，临床效果及安全性均较好。从mRs评分上看，溶栓前、加重时、用药 24小时mRs评分差异无统计学意义(P &gt; 0.05)，用药14天、90天时差异有统计学意义(P &lt; 0.05)表明穿支动脉脑梗死静脉溶栓后无效或再闭塞早期给予替罗非班治疗可以有效的改善患者的远期预后。这基本与JUNGHANS [<xref ref-type="bibr" rid="hanspub.43446-ref20">20</xref>] 等研究结论一致即替罗非班可改善穿支动脉闭塞型脑卒中患者神经功能。</p><p>不良事件对比，观察组卒中后抑郁占3.3%，对照组为26.6%，差异有统计学意义(P &lt; 0.05)，可见穿支动脉脑梗死静脉溶栓后无效或再闭塞早期给予替罗非班治疗可改善患者神经功能及临床预后，能进一步减轻患者发生抑郁风险，有利于患者身心健康；再梗死观察组为6.6%，对照组为36.6%，差异有统计学意义(P &lt; 0.05)，可见，在静脉溶栓治疗基础上，联合替罗非班治疗急性穿支动脉型脑梗死，可以降低血栓发生概率，改善患者的预后；脑出血观察组为10%，对照组为3.3%，差异无统计学意义(P &gt; 0.05)；死亡率观察组为3.3%，对照组为10%，差异无统计学意义(P &gt; 0.05)，表明早期联合替罗非班治疗是相对安全的，没有增加出血、死亡的风险。高尿酸血症被认为是脑血管病的独立危险因素，与脑梗死发病呈正相关，其引起脑梗死的主要机制为高尿酸血症可导致机体炎症反应及氧化应激，使血管内皮受损，清除自由基能力下降，血液粘稠度增加，导致动脉粥样硬化、血栓形成。通过对两组患者尿酸水平检测可以看出，两组治疗前尿酸水平对比差异无统计学意义(P＞0.05)，两组治疗后尿酸水平对比差异有统计学意义(P &lt; 0.05)观察组治疗效果优于对照组，表明rt-PA联合替罗非班治疗可减轻穿支动脉闭塞性脑梗死炎性反应，降低尿酸水平，与刘玲 [<xref ref-type="bibr" rid="hanspub.43446-ref21">21</xref>] 等研究基本相符。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，急性穿支动脉闭塞性脑梗死患者给予静脉溶栓药物联合替罗非班治疗较单用静脉溶栓药物可更好地改善患者的神经功能，减少再闭塞率、卒中后抑郁率，改善患者生活质量，利于身心健康，没有增加症状性脑出血、死亡等风险，并且可降低体内尿酸水平，优化内环境，值得临床应用。</p></sec><sec id="s10"><title>文章引用</title><p>高振红,周 畅,高振文,王仰亮,邵可可. 阿替普酶联合替罗非班治疗穿支动脉闭塞性脑梗死的疗效及安全性Efficacy and Safety of Alteplase Combined with Tirofiban in the Treatment of Perforating Artery Occlusive Cerebral Infarction[J]. 临床医学进展, 2021, 11(06): 2836-2843. https://doi.org/10.12677/ACM.2021.116412</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43446-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">刘丽萍, 陈玮琪, 段婉莹, 等. 中国脑血管病临床管理指南(节选版)——缺血性脑血管病临床管理[J]. 中国卒中杂志, 2019, 14(7): 709-726.</mixed-citation></ref><ref id="hanspub.43446-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rhalish, J.H., Saver, J.L. and Simpson, S.H. (2007) The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis. Stroke, 38, 967-973. &lt;br&gt;https://doi.org/10.1161/01.STR.0000258112.14918.24</mixed-citation></ref><ref id="hanspub.43446-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Saqqur, M., Molina, C.A., Salam, A., et al. (2007) Clinical Deterioration after Intravenous Recombinant Tissue Plasminogen Activator Treatment: A Multicenter Transcranial Doppler Study. Stroke, 38, 69-74.  
&lt;br&gt;https://doi.org/10.1161/01.STR.0000251800.01964.f6</mixed-citation></ref><ref id="hanspub.43446-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bailey, E.L., Smith, C., Sudlow, C.L., et al. (2012) Pathology of Lacunar Ischemic Stroke in Humans—A Systematic Review. Brain Pathology, 22, 583-591. &lt;br&gt;https://doi.org/10.1111/j.1750-3639.2012.00575.x</mixed-citation></ref><ref id="hanspub.43446-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018 [J]. 中华神经科杂志, 2018, 51(9): 666.</mixed-citation></ref><ref id="hanspub.43446-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Lin, L., Zhang, M., et al. (2016) Safety and Preliminary Efficacy of Early Tirofiban Treatment after Alteplase in Acute Ischemic Stroke Patients. Stroke, 47, 2649-2651. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.116.014413</mixed-citation></ref><ref id="hanspub.43446-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">张文华, 孙冠军, 崔海峰, 等. 阿替普酶超时间窗溶栓治疗急性脑梗死37例临床分析[J]. 中华实用诊断与治疗杂志, 2014, 28(8): 792-793, 795.</mixed-citation></ref><ref id="hanspub.43446-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杨雅文, 李倩, 田成林, 等．穿支动脉区脑梗死部位分布的临床研究[J]. 中华老年心脑血管病杂志, 2015, 17(5): 439-471.</mixed-citation></ref><ref id="hanspub.43446-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, T.-F., Zhu, L.-F., Li, T.-X., et al. (2018) Treatment of Acute Atherosclerotic Anterior Circulation of Large Vessels Occlusion by Endovascular Recanalization. Journal of Neurosurgery, 34, 253-257.</mixed-citation></ref><ref id="hanspub.43446-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Meng, J.X., He, S., Xie, H.F., et al. (2018) Analysis of the Adverse Effects of Alteplase on Bleeding in Patients with Acute Cerebral Infarction. Chinese Journal of Clinical Pharmacology, 34, 1595-1597.</mixed-citation></ref><ref id="hanspub.43446-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">占达良, 王晟, 张耿. 影响急性脑梗死患者预后的入院前相关因素分析[J]. 中国卫生统计, 2018, 35(4): 569-571.</mixed-citation></ref><ref id="hanspub.43446-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">魏东, 杨宗军, 王晓晶. 急性脑梗死患者血清超敏C-反应蛋白和纤维蛋白原检测的临床意义[J]. 山东医药, 2018, 58(33): 77-79.</mixed-citation></ref><ref id="hanspub.43446-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.I., Gliem, M., Gerdes, G., et al. (2017) Safety of Bridging Antiplatelet Therapy with the gp IIb-Ⅲa Inhibitor Tirofiban after Emergency Stenting in Stroke. PLoS ONE, 12, e0190218. &lt;br&gt;https://doi.org/10.1371/journal.pone.0190218</mixed-citation></ref><ref id="hanspub.43446-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nazif, T.M., Mehran, R., Lee, E.A., et al. (2014) Comparative Effectiveness of Upstream Glycoprot and High-Risk Acute Coronary Syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUINY) Substudy. American Heart Journal, 167, 43-50. &lt;br&gt;https://doi.org/10.1016/j.ahj.2013.10.013</mixed-citation></ref><ref id="hanspub.43446-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">许丽华, 陶琳, 周安, 等. 替罗非班在急性脑梗死介入治疗中的应用[J]. 继续医学教育, 2018, 32(1): 163-164.</mixed-citation></ref><ref id="hanspub.43446-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">邱涛, 戴晓艳, 黄琳明, 等. 小牛血清去蛋白联合替罗非班治疗进展性脑梗死的疗效观察[J]. 现代药物与临床, 2016, 31(7): 965-968.</mixed-citation></ref><ref id="hanspub.43446-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Siebler, M., Hennerici, M.G., Schneider, D., et al. (2011) Safety of Tirofiban in Acute Ischemic Stroke: The SaTIS trial. Stroke, 42, 2388-2392. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.110.599662</mixed-citation></ref><ref id="hanspub.43446-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Philipps, J., Thomalla, G., Glahn, J., et al. (2001) Bleeding Risk of Tirofiban, a Nonpeptide GPIIb/IIIa Platelet Receptor Antagonist in Progressive Stroke: An Open Pilot Study. Cerebrovascular Diseases, 12, 308-312.  
&lt;br&gt;https://doi.org/10.1159/000047726</mixed-citation></ref><ref id="hanspub.43446-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">孙原, 石秋艳, 李艳玲, 杨斌, 张春阳, 李冬梅, 王翠兰, 李弘. 替罗非班治疗阿替普酶静脉溶栓后再闭塞的疗效观察[J]. 中国实用神经疾病杂志, 2018, 21(1): 40-43.</mixed-citation></ref><ref id="hanspub.43446-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Junghans, U., Seitz, R.J., Aulich, A., et al. (2001) Bleeding Risk of Tirofiban, a Nonpeptide GPIIb/IIIa Platelet Receptor Antagonist in Progressive Stroke: An Open Pilot Study. Cerebrovascular Diseases, 12, 308-312.  
&lt;br&gt;https://doi.org/10.1159/000047726</mixed-citation></ref><ref id="hanspub.43446-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">刘玲, 陶瑞明, 杨亚东, 等. 替罗非班治疗急性脑梗死患者的疗效及对炎性因子的影响[J]. 心脑血管病防治, 2018, 18(1): 39-41.</mixed-citation></ref></ref-list></back></article>